Overview Cumulus Neuroscience published final CNS-102 results showing that its at-home NeuLogiq platform is feasible and well tolerated in people with ALS and FTD. The platform combines at-home EEG wi...
Cumulus NeuLogiq Platform Demonstrates Year-Long Home Use in Mild Alzheimer’s Disease Dementia Study
Overview The News Cumulus Neuroscience has published final results from its CNS-101 study in Frontiers in Digital Health, demonstrating the feasibility of using th...
